Bp102 (Not yet branded)

Other Medications

US Experimental EU Experimental ES med_spain_not_available IV 4 Clinical Trials
Unknown specific target

Description

Bp102 is currently in experimental stages for colorectal cancer and has not been approved by the FDA. Its clinical efficacy and safety profile are still under investigation, with ongoing studies evaluating its potential role as a therapeutic option in advanced or metastatic CRC.

Mechanism of Action

Bp102 is an investigational agent with an unknown specific molecular target; its mechanism of action is currently under research and not fully elucidated.

Molecular Targets

Side Effects

Adverse reactions are currently unknown; further clinical trials are needed to define the safety profile of Bp102.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07061210 med_phase_prefix2
Not yet recruiting
An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
NCT06679673 med_phase_prefix2
Not yet recruiting
SHR-1701 Combined with SHR2554 and BP102 for MCRC
China
NCT06373133 med_phase_prefix1
Not yet recruiting
SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
NCT03645876 med_phase_prefix2
Archived
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
China

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
EU Estado EMAExperimental
ES Acceso Españamed_spain_not_available
AdministrationIV
Clinical Trials4
View Clinical Trials Back to Drug Glossary

Related Medications

SHR-8068
Other Medications
4 trials
T3011
Other Medications
3 trials
Dsp107
Other Medications
2 trials
NC410
Other Medications
2 trials
Krn330
Other Medications
2 trials
Muzastotug
Other Medications
1 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.